Virtual Care in Oncology: Commercialization Models

Cancer is a source of significant and growing mortality worldwide. In 2020, it was the therapeutic area with more capital invested in digital health, 12% of venture funding in digital health was focused on oncology companies. Recent results (https://cutt.ly/RjIOIS9 & https://cutt.ly/njIOPM5) show that digital symptom monitoring during chemotherapy can help patients improve quality of life, live longer and reduce hospitalisation and ER visits. But having the results is not enough; identifying the best routes to market is key to be successful. Join this informal conversation to discuss:

• What is the best option to get paid for a digital solution in oncology? E.g D2C, pharma and medtech (as companion to their products), Saas product for hospital systems, academic medical centers, payers, employers, others? 

• How do we successfully blend together different routes to market (e.g D2C + employers, D2C + hospitals)?

• What are the implications of choosing one route to market vs. others in terms of evidence requirements, pricing strategies, product iterations, etc?

• What are the factors that determine the best route to market (e.g geographies, type of cancer, objective of the program -prevention, diagnosis, management, etc-, others)?